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Abstract 
The U.S. Food and Drug Administration (FDA) cautions 
health care providers and patients regarding the use of tes-
tosterone replacement therapy products for the aging pro-
cess, including a decrease in muscle strength, muscle mass, 
and lack of energy or sexual desire, due to an increased risk 
of heart attacks and strokes. Testosterone replacement ther-
apy products are indicated for genetic defects, chemotherapy 
damage, or damage to the hypothalamus or pituitary gland, 
where testosterone is produced. A patient and his team of 
health care professionals must seriously consider the risks 
and benefits when using these products for other indications. 
Use of testosterone replacement therapy products for low 
testosterone due to natural aging has been on the rise due to 
disease state awareness, pharmaceutical marketing and me-
dia attention. Pharmacists can make a difference in patients' 
lives by conducting patient education and counseling for 
these products. 
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lntroduction 
Testosterone replacement therapy (TRT) has received recent 
attention in the scientific community as the U.S. Food and 
Drug Administration (FDA) has communicated that caution 
should be advised when using testosterone products for the 
aging process, including for symptoms such as declining 
muscle mass, muscle strength and libido. In September 2014, 
the FDA used input from an advisory committee of experts to 
conclude that there may be an increased cardiovascular risk 
with testosterone use.1 With a March 2015 update, the FDA 
states that testosterone products are now required to in-
clude labels indicating increased risk of heart attacks and 
strokes. Health care providers are encouraged to inform 
their patients of these risks.t 
Testosterone replacement therapy products are indicated in 
male patients who have genetic defects causing lack of tes-
tosterone production by the testes, damage from chemother-
apy to the testes or damage to the hypothalamus or pituitary 
gland. However, many males who receive testosterone prod-
ucts have been diagnosed with idiopathic hypogonadism, 
which is a low level of testosterone due to no other deter-
mined reason except for aging. Within the past six years, 
there has been a significant increase in the use of TRT prod-
ucts; 1.3 million patients received TRT prescriptions in 2009 
compared to 2.3 million in 2013, with 70 percent of those 
patients between the ages of 40 and 64 years.2 The increase 
in use of TRT may be due to confounding factors including 
the rise in the baby boomer generation, pharmaceutical mar-
keting or media attention for low testosterone. Moreover, 
with the use of TRT nearly doubling in recent years, ongoing 
investigational research studying the potentially harmful, 
long-term effects of TRT is invaluable. Patients obtain medi-
cal advice from numerous outlets, many of them unreliable. 
Thus, it is important that health care professionals are aware 
of current research to provide appropriate and trustworthy 
clinical advice and counseling to all patients. 
Hypogonadism and Testosterone Replacement Therapy 
Recommendations 
Hypogonadism is the manifestation of testosterone deficien-
cy or infertility in males, the symptoms of which vary de-
pending on age. Symptoms in males before puberty include 
small testes, phallus and prostate, decreased growth of pubic 
hair, delayed epiphyseal closure resulting in disproportion-
ately long limbs, gynecomastia, high-pitched voice and loss of 
testicular function. Older patients with lower levels of testos-
terone may experience fatigue, decreased libido, impotence, 
decreased sperm production, loss of lean muscle mass, hot 
flashes and osteoporosis. 3 
Testosterone replacement therapy may be prescribed to pa-
tients with low testosterone levels to reduce the severity of 
these symptoms and, improve the patient's overall quality of 
life. Short-term studies have shown an increase in lean body 
mass and production of blood cells and a decrease in low-
density lipoprotein (LDL) levels in patients using hormone 
replacement. Libido has also been shown to improve in older 
men.3 
The American Association of Clinical Endocrinologists 
(AACE) and American College of Endocrinology protocol for 
standardized production of clinical guidelines recommend 
the use of testosterone replacement for the following indica-
tions: 
• Management of congenital or acquired primary 
hypogonadism resulting from orchiectomy (surgical 
removal of one or both testes) or testicular failure. 
• Management of congenital or acquired primary 
hypogonadism resulting from idiopathic gonadotro-
pin/gonadotropin-re\easing hormone deficiency or 
from pituitary-hypothalamic injury caused by tumors, 
trauma or radiation. 
• Androgen deficiency and acquired immune deficiency 
syndrome (AIDS) wasting in human immunodeficiency 
virus (HIV)-infected men. 
• Low serum testosterone concentrations (less than 300 
ng/dL) in patients receiving long-term corticosteroid 
therapy. 
• Improvement of body composition, strength, bone 
density, frailty, cognitive function, mood, sexual 
function, quality of life and to induce secondary sex 
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characteristics in men with symptomatic androgen de-
ficiency when the benefits outweigh potential risks.4.s 
The Endocrine Society has recommended that a patient be 
diagnosed with androgen deficiency only when displaying 
consistent symptoms of low serum testosterone levels diag-
nosed by measuring morning total testosterone levels by a 
reliable assay. Measurement of total testosterone levels 
should be repeated for confirmation. The panel of experts 
disagreed on the exact level of serum testosterone. Some 
panelists saw the benefits of treating patients with serum 
testosterone levels of 280 to 300 ng/dL, which is the lower 
limit of normal for a healthy adult male. Clinical trial data 
indicates a level of 200 ng/dL or less would be appropriate 
for diagnosis and initiation of replacement therapy. Goal tes-
tosterone levels, once replacement therapy has been initiat-
ed, should be mid-normal levels (normal range 300 to 1,050 
ng/dL) and consistently monitored.6,7 
The Endocrine Society has recommended against the use of 
TRT in patients with breast or prostate cancer or a palpable 
prostate nodule. It is also not recommended to use TRT in 
patients with levels of prostate-specific antigen (PSA), a gly-
coprotein enzyme that can serve as a biomarker for prostate 
disorders, above 4 ng/dL or in men at high risk for prostate 
cancer.6 It is the general consensus of both the FDA and En-
docrine Society that TRT should not be generally offered to 
all older male patients with low testosterone levels.1.6 Before 
testosterone therapy is recommended, physicians should 
discuss the potential risks and benefits with their patients.6 
Use of TRT for erectile dysfunction is currently not an FDA 
labeled use in men with normal serum testosterone levels, 
although it has been prescribed for this indication.1.6 Because 
men presenting with hypogonadism tend to have increased 
likelihood of mood disturbances including depression, low 
self-esteem and learning problems, it is recommended that 
TRT be combined with psychiatric counseling for the most 
beneficial results.3 
Testosterone replacement therapy seems to have a positive 
effect on patients' symptoms and quality of life in short-term 
follow-up. However, research evaluating the long-term ef-
fects of TRT is scarce. Studies assessing the potential cardio-
vascular complications and cancerous associations with TRT 
have shown conflicting results. Ongoing long-term research 
and increased awareness of the potential risks will only help 
improve patient care.3 
Increased use ofTRT in Men and Performance Enhancement 
Idiopathic hypogonadism associated with aging has been 
shown to affect between 5 percent and 40 percent of males 
between the ages of 40 and 79 years. Lower testosterone 
levels manifest in ways that can deeply affect a patient's 
quality of life, but may not warrant immediate action from a 
physician. However, in recent years, there has been in-
creased awareness of this disorder which has resulted in 
increased prescribing for testosterone replacement. Largely 
due to media attention and pharmaceutical marketing, pa-
tients have begun to seek treatment for hypogonadism. This 
can be evidenced by the 500 percent increase in prescrip-
tions since 1993.7 Most likely stemming from a desire to re-
tain the level of wellness and physical activity one had at a 
younger age, consumer spending on testosterone therapies 
has exponentially increased. In 2011, $1.6 billion was spent 
on TRT prescriptions, almost tripling what was spent in 
2006.8 
Also contributing to the surge of TRT prescriptions is use of 
testosterone for enhancement of physique and increased 
muscle mass used most significantly by athletes and body-
builders. According to the New England Journal of Medicine, 
androgen therapy for the purpose of performance enhance-
ment began in the1940s and has since skyrocketed. Doses of 
TRT for performance enhancement are 100 times larger than 
those used for appropriate indications and require signifi-
cant periods of time off therapy in order to allow the body to 
recover from adverse reactions caused by such large doses.9 
As the baby boomer generation ages and direct-to-consumer 
advertising becomes more popular, TRT prescriptions are 
projected to increase. Without readily available research of 
long-term TRT or the proper awareness of potential compli-
cations of TRT, concern for patient safety should be of the 
utmost importance.10 
Risks Associated with Testosterone Replacement Therapy 
It is currently agreed upon that there may be some long-term 
risks involving TRT. The AACE published a comprehensive 
report on treating men with hypogonadism, reporting on 
TRT as a treatment option and the identification of potential 
side effects that might accompany treatment.3 One potential 
adverse event is cardiovascular morbidity. However, a con-
sensus has not been reached as to how TRT and testosterone 
levels in the aging male body affect cardiovascular health. 
There is a large body of literature suggesting that testos-
terone therapy may increase the risk of certain adverse car-
diovascular events, including nonfatal myocardial infarction 
and stroke in older men (due to testosterone's tendency to 
increase platelet aggregation), and in young men with 
preexisting heart conditions.3,10,11 
In 2010, Malkin and colleagues published a paper suggesting 
that low serum testosterone (i.e., endogenous) levels corre-
late with increased mortality in men with coronary heart 
disease.12 Other work by Malkin and his colleagues has 
demonstrated that testosterone therapy improves functional 
capacity and reduces symptom severity in men with moder-
ate severity heart failure.13 The important distinction to 
make between the conflicting evidence is that low endoge-
nous testosterone levels were related to adverse cardiovascu-
lar effects, whereas TRT, by definition, introduces exogenous 
testosterone to the endocrine system. This does, however, 
raise questions as to whether it is worth the risk to utilize 
TRT as a treatment for hypogonadism in male patients with 
preexisting cardiovascular risks. 
In addition to the adverse effects that TRT may have on car-
diovascular health, the AACE report also emphasizes the 
need to evaluate elevated risks of prostate cancer that may 
or may not be associated with TRT.3 It has already been es-
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tablished that patients with prostate cancer are not recom-
mended to receive TRT.3,4 However, it is less clear as to 
whether there is a direct relationship between TRT and in-
creased risk of prostate cancer in cancer-free patients at 
baseline. A 2005 paper from the Brady Urological Institute at 
Johns Hopkins Hospital showed a correlation between high 
levels of free serum testosterone with higher incidences of 
prostate cancer, leading the authors to directly call into ques-
tion the safety of TRT as it relates to elevated risk of prostate 
cancer.14 Information regarding adverse effects and formula-
tion-specific adverse effects of TRT are presented below in 
Table 1 and Table 2. 
In the opposing camp, Rhoden and Morgentaler (2003) 
concluded that TRT is not an ill-advised treatment option in 
hypogonadic patients, even in those who have prostatic 
intraepithelial neoplasia (PIN), a precancerous prostatic 
lesion that often leads to the development of prostate 
cancer.ls In a later 2010 study, Morgentaler and colleagues 
further concluded that testosterone therapy in men with un-
treated prostate cancer was not associated with progression 
of the disease in the first three to 12 months. They recom-
mended that the discouraged use of testosterone therapy in 
men with less severe prostate cancer or treated prostate can-
cer should be reconsidered.14 Recently, TRT is being consid-
Potential Adverse Side Effects and Various Types of Testosterone Replacement Therapy.s 
Table 1. General Testosterone Administration Adverse Effects. 
Adverse events for which there is evidence of association Erythrocytosis 
with testosterone administration Acne and oily skin 
Detection of subclinical prostate cancer 
Growth of metastatic prostate cancer 
Reduced sperm production and fertility 
Uncommon adverse events for which there is weak evidence Gynecomastia 
of association with testosterone administration Male pattern balding (familial) 
Growth of breast cancer 
Induction or worsening of obstructive sleep apnea 
Table 2. Formulations and Formulation Specific Adverse Effects. 
Formulation Specific Adverse Effects 
Intramuscular injections of testosterone ethanate, Fluctuation in mood or libido 
cypionate or undecanoate Pain at injection site 
Excessive erythrocytosis (especially in older patients) 
Coughing episodes immediately after the intramuscular 
injection* 
Transdermal patches Frequent skin reactions at application site 
Transdermal gel Potential risk for testosterone transfer to partner or 
another person who is in close contact (need to 
remind patient to cover application sites with clothing 
and to wash skin and hands with soap before having 
skin-to-skin contact with another person) 
Skin irritation 
Buccal testosterone tablets Alterations in taste 
Irritation of gums 
Pellet Implants Infection, expulsion of pellet 
Oral tablets Effects on liver and cholesterol (methyltestosterone)t 
*The mechanism of cough, which has been reported rarely after intramuscular injections of testosterone undecanoate and even more 
rarely after testosterone enanthate and cypionate, is unknown, but it has been attributed to oil embolization. 
tLiver toxicity has been reported mostly with oral 17-alpha alkylated androgens. The frequency of skin reactions is higher with the 
testosterone patch than with the transdermal gels. 
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ered in patients with hypogonadism associated with prostate 
cancer comorbidities in some cases, although consistent 
monitoring is strictly encouraged.15 
Monitoring Parameters 
Treatment monitoring is important to ensure the patient 
safety remains at the center of all individualized therapy reg-
imens. Testosterone and its byproducts stimulate the growth 
of the prostate gland and seminal vesicles. While current re-
search has failed to definitively prove a direct correlation 
between TRT and increased PSA levels or abnormal prostate 
growth, monitoring of these parameters is still essential. Fol-
low-up appointments every three to four months is crucial 
for all patients receiving TRT during the first year of thera-
py.13 Patients receiving injected testosterone should have 
their serum testosterone measured at the midpoint between 
injections; the level should be within a mid-normal range.3 
Digital rectal exams (DRE) are recommended every six to 12 
months and PSA levels should be measured annually in older 
males. If PSA levels are determined to be abnormally high 
(greater than 4 ng/dL), TRT should be discontinued and the 
patient may need to be referred for urologic consult. In pa-
tients concurrently receiving finasteride, further evaluation 
may be warranted if PSA levels show a significant increase.3 
Because testosterone increases production of blood cells by 
the bone marrow, hematocrit should also be routinely moni-
tored every six to 12 months so that coagulation does not 
result. TRT should be discontinued if hematocrit rises above 
50 percent. Other side effects reported with testosterone 
therapy include gynecomastia resulting from the chemical 
change testosterone undergoes in the body to produce estro-
gen and an increased risk of alopecia. This should be consid-
ered when assessing the risk versus benefit analysis for each 
patient.14 
How Can Pharmacists Help? 
As with any prescription, counseling from a pharmacist is 
highly recommended. Considering the added risks of 
hormone therapy, patient education of TRT is a necessity. 
Testosterone therapy is available in a wide range of formula-
tions including injection, transdermal patches and topical 
gels, each with their own set of precautions and specific 
directions for application. Successful and safe utilization of 
therapy for each patient requires thorough comprehension 
of their TRT prescriptions. 
It is also important that a patient be equipped with all the 
relevant information regarding the risks of initiating TRT at 
the point of prescribing. Physicians should attempt to pre-
sent accurate information to each patient, especially in a so-
ciety where faulty information is only a click away, and help 
the patients make the best possible decision in accordance 
with their own individual health and wellness. 
Conclusion 
Testosterone therapies are a rapidly-growing option for ag-
ing men that will continue to expand with the aging of the 
baby boomer generation, due to a higher incidence of hy-
pogonadism in the aging population. Increased use of TRT 
coupled with its high potential for abuse make counseling 
and education an essential step for pharmacists at the time of 
dispensing. The growing demand for testosterone replace-
ment in conjunction with the FDA requirement to label the 
increased risk of heart attacks and strokes on testosterone 
products necessitates that health care providers utilize cau-
tion when prescribing these therapies and share their aware-
ness of the potential risks and benefits associated with using 
these products with patients.I 
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